Related Experiment Video
Updated: May 31, 2026
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Kaempferol-based nanocarriers as a potential therapeutic strategy against drug-resistant lung cancer
Pouya Goleij1,2,3, Mohammad Amin Khazeei Tabari3,4, Danaé S Larsen5
1USERN Office, Kermanshah University of Medical Sciences, Kermanshah, 6715847141, Iran.
Abstract:
Lung cancer is the predominant cause of cancer-related deaths, with chemoresistance posing a significant challenge for effective treatment. Drug resistance in lung cancer cells involves various cellular and molecular mechanisms, including the upregulation of DNA repair pathways, activation of secondary proto-oncogenes and alterations in cell cycle regulation, apoptosis and the tumor microenvironment. Recent advances in nanotechnology have paved the way for innovative approaches to overcome chemoresistance, particularly through the utilization of nanocarriers for targeted drug delivery. When encapsulated within nanocarriers, kaempferol's therapeutic potential is significantly enhanced, offering improved bioavailability, targeted delivery and reduced systemic toxicity. Kaempferol-based nanoparticles, including liposomes, solid lipid nanoparticles, and nanostructured lipid carriers, have shown substantial efficacy for combating chemoresistance in lung cancer models. These nanoparticles May enhance the intracellular delivery of kaempferol, potentially leading to the inhibition of key signaling pathways implicated in chemoresistance. Additionally, kaempferol-based nanocarriers have been shown to sensitize cancer cells to conventional chemotherapeutic agents, reducing drug efflux and enhancing apoptosis. The synergistic effects of kaempferol in combination with chemotherapy drugs, including cisplatin and 5-fluorouracil, further underscore its potential in overcoming resistance mechanisms. Moreover, the use of hyaluronic acid-modified, kaempferol-based nanoparticles has demonstrated enhanced targeting of lung cancer cells, inhibition of epithelial-to-mesenchymal transition and suppression of tumor invasion and metastasis.
Insights
Kaempferol-loaded nanoparticles show promise in overcoming chemoresistance in lung cancer by enhancing drug delivery and sensitizing cells to chemotherapy. These nanocarriers offer a targeted approach to improve treatment efficacy and reduce toxicity.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Lung cancer is a leading cause of cancer mortality, with chemoresistance significantly limiting treatment effectiveness.
- Mechanisms of chemoresistance include altered DNA repair, cell cycle regulation, apoptosis, and the tumor microenvironment.
- Nanotechnology offers novel strategies for targeted drug delivery to overcome chemoresistance.
Purpose of the Study:
- To evaluate the efficacy of kaempferol-loaded nanocarriers in overcoming chemoresistance in lung cancer.
- To investigate the mechanisms by which kaempferol nanoparticles enhance drug delivery and chemosensitivity.
- To explore the synergistic effects of kaempferol-based nanocarriers with conventional chemotherapy.
Main Methods:
- Encapsulation of kaempferol into various nanocarrier systems (liposomes, SLNs, NLCs).
- Assessment of nanoparticle-mediated intracellular drug delivery and inhibition of chemoresistance pathways.
- Evaluation of synergistic effects with chemotherapeutic agents like cisplatin and 5-fluorouracil.
- Utilizing hyaluronic acid-modified nanoparticles for enhanced lung cancer cell targeting.
Main Results:
- Kaempferol-loaded nanoparticles demonstrated enhanced bioavailability, targeted delivery, and reduced systemic toxicity.
- Nanoparticles improved intracellular delivery of kaempferol, inhibiting key chemoresistance signaling pathways.
- Kaempferol nanocarriers sensitized lung cancer cells to chemotherapy, reducing drug efflux and promoting apoptosis.
- Synergistic effects observed with cisplatin and 5-fluorouracil.
- Hyaluronic acid modification enhanced lung cancer cell targeting and inhibited epithelial-to-mesenchymal transition.
Conclusions:
- Kaempferol-based nanocarriers represent a promising strategy to combat chemoresistance in lung cancer.
- Nanotechnology enhances kaempferol's therapeutic potential, improving targeted delivery and efficacy.
- Combination therapy with kaempferol nanocarriers and chemotherapy offers a synergistic approach to overcome resistance.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers